Q4 2021 Results
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
BeovuⓇ
-
VEGF Inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04278417 (CRTH258D2301)
Diabetic retinopathy
Phase 3
706
Change from Baseline in BCVA
Arm1: RTH258 (brolucizumab) 6 mg/50uL
Arm2: Panretinal photocoagulation laser initial treatment followed with additional
PRP treatment as needed
Patients with proliferative diabetic retinopathy
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
108 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation